{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:08Z","timestamp":1786980908622,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Alchemia Oncology","award":["ACO-003"],"award-info":[{"award-number":["ACO-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10637-017-0555-8","type":"journal-article","created":{"date-parts":[[2017,12,25]],"date-time":"2017-12-25T20:49:06Z","timestamp":1514234946000},"page":"288-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-2350","authenticated-orcid":false,"given":"Muhammad","family":"Alamgeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neil Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Banakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Markman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,26]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","unstructured":"Alamgeer M, Ganju V, Kumar B et al. (2014) Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer breast cancer research : BCR 16:R44, doi:https:\/\/doi.org\/10.1186\/bcr3648","DOI":"10.1186\/bcr3648"},{"key":"555_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1136\/thoraxjnl-2012-203021","volume":"68","author":"M Alamgeer","year":"2013","unstructured":"Alamgeer M, Ganju V, Szczepny A et al (2013) The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68:1095\u20131104. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-203021","journal-title":"Thorax"},{"key":"555_CR3","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","volume":"10","author":"WJ Allard","year":"2004","unstructured":"Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical cancer research : an official journal of the American Association for Cancer Research 10:6897\u20136904. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0378","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2003.10.003","volume":"44","author":"M Ando","year":"2004","unstructured":"Ando M, Kobayashi K, Yoshimura A et al (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44:121\u2013127. https:\/\/doi.org\/10.1016\/j.lungcan.2003.10.003","journal-title":"Lung Cancer"},{"key":"555_CR5","first-page":"143","volume":"9","author":"A Ardizzoni","year":"2003","unstructured":"Ardizzoni A, Manegold C, Debruyne C et al (2003) European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 9:143\u2013150","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1593\/neo.07229","volume":"9","author":"E Auzenne","year":"2007","unstructured":"Auzenne E, Ghosh SC, Khodadadian M et al (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9:479\u2013486","journal-title":"Neoplasia"},{"key":"555_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1468-3083.2004.01180.x","volume":"19","author":"MB Brown","year":"2005","unstructured":"Brown MB, Jones SA (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of the European Academy of Dermatology and Venereology : JEADV 19:308\u2013318. https:\/\/doi.org\/10.1111\/j.1468-3083.2004.01180.x","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"key":"555_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.3-1-1","volume":"3","author":"HA Burris 3rd","year":"1998","unstructured":"Burris HA 3rd (1998) Topotecan: incorporating it into the treatment of solid tumors. Oncologist 3:1\u20133","journal-title":"Oncologist"},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7:1748\u20131756","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"555_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1200\/JCO.2008.20.2127","volume":"27","author":"G Chen","year":"2009","unstructured":"Chen G, Huynh M, Fehrenbacher L et al (2009) Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:1401\u20131404. https:\/\/doi.org\/10.1200\/JCO.2008.20.2127","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"555_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ctrv.2004.06.003","volume":"30","author":"YJ Chua","year":"2004","unstructured":"Chua YJ, Steer C, Yip D (2004) Recent advances in management of small-cell lung cancer. Cancer Treat Rev 30:521\u2013543. https:\/\/doi.org\/10.1016\/j.ctrv.2004.06.003","journal-title":"Cancer Treat Rev"},{"key":"555_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"555_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.bbamem.2013.01.020","volume":"1828","author":"E Dalla Pozza","year":"2013","unstructured":"Dalla Pozza E, Lerda C, Costanzo C et al (2013) Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta 1828:1396\u20131404. https:\/\/doi.org\/10.1016\/j.bbamem.2013.01.020","journal-title":"Biochim Biophys Acta"},{"key":"555_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/83.12.855","volume":"83","author":"M Fukuoka","year":"1991","unstructured":"Fukuoka M, Furuse K, Saijo N et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855\u2013861","journal-title":"J Natl Cancer Inst"},{"key":"555_CR15","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1016\/j.biomaterials.2013.01.077","volume":"34","author":"S Ganesh","year":"2013","unstructured":"Ganesh S, Iyer AK, Morrissey DV, Amiji MM (2013) Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34:3489\u20133502. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.01.077","journal-title":"Biomaterials"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000180339","volume":"55","author":"P Gibbs","year":"2009","unstructured":"Gibbs P, Brown TJ, Ng R et al (2009) A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. Chemotherapy 55:49\u201359. https:\/\/doi.org\/10.1159\/000180339","journal-title":"Chemotherapy"},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00280-010-1303-3","volume":"67","author":"P Gibbs","year":"2011","unstructured":"Gibbs P, Clingan PR, Ganju V et al (2011) Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol 67:153\u2013163. https:\/\/doi.org\/10.1007\/s00280-010-1303-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"555_CR18","doi-asserted-by":"publisher","unstructured":"Han D, Wang G, Sun L, Ren X, Shang W, Xu L, Li S (2017) Comparison of irinotecan\/platinum versus etoposide\/platinum chemotherapy for extensive-stage small cell lung cancer: a meta-analysis. Eur J Cancer Care (Engl) 26. https:\/\/doi.org\/10.1111\/ecc.12723","DOI":"10.1111\/ecc.12723"},{"key":"555_CR19","doi-asserted-by":"publisher","unstructured":"Hanna N, Bunn PA, Jr., Langer C et al. (2006) Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24:2038\u20132043 doi:https:\/\/doi.org\/10.1200\/JCO.2005.04.8595","DOI":"10.1200\/JCO.2005.04.8595"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2007.15.7545","volume":"26","author":"A Hermes","year":"2008","unstructured":"Hermes A, Bergman B, Bremnes R et al (2008) Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 26:4261\u20134267. https:\/\/doi.org\/10.1200\/JCO.2007.15.7545","journal-title":"J Clin Oncol"},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-12-3801","volume":"73","author":"T Hiraga","year":"2013","unstructured":"Hiraga T, Ito S, Nakamura H (2013) Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 73:4112\u20134122. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3801","journal-title":"Cancer Res"},{"key":"555_CR22","first-page":"1108","volume":"58","author":"T Hirata","year":"1998","unstructured":"Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 58:1108\u20131110","journal-title":"Cancer Res"},{"key":"555_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1040-8428(04)00151-9","volume":"52","author":"A Kurup","year":"2004","unstructured":"Kurup A, Hanna NH (2004) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52:117\u2013126. https:\/\/doi.org\/10.1016\/j.critrevonc.2004.08.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"555_CR24","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","volume":"27","author":"PN Lara Jr","year":"2009","unstructured":"Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530\u20132535. https:\/\/doi.org\/10.1200\/JCO.2008.20.1061","journal-title":"J Clin Oncol"},{"key":"555_CR25","first-page":"3632","volume":"7","author":"Z Luo","year":"2014","unstructured":"Luo Z, RR W, Lv L, Li P, Zhang LY, Hao QL, Li W (2014) Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 7:3632\u20133646","journal-title":"Int J Clin Exp Pathol"},{"issue":"Suppl 1","key":"555_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000227106","volume":"49","author":"N Masuda","year":"1992","unstructured":"Masuda N, Fukuoka M, Furuse K (1992a) CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology 49(Suppl 1):19\u201324","journal-title":"Oncology"},{"key":"555_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1200\/JCO.1992.10.8.1225","volume":"10","author":"N Masuda","year":"1992","unstructured":"Masuda N, Fukuoka M, Kusunoki Y et al (1992b) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10:1225\u20131229","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"555_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.1742-4658.2011.08071.x","volume":"278","author":"S Misra","year":"2011","unstructured":"Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278:1429\u20131443. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08071.x","journal-title":"FEBS J"},{"key":"555_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000030154","volume":"22","author":"E Mizera-Nyczak","year":"2001","unstructured":"Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J (2001) Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 22:45\u201353","journal-title":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"555_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/JTO.0b013e31823f125d","volume":"7","author":"T Naito","year":"2012","unstructured":"Naito T, Tanaka F, Ono A et al (2012) Prognostic impact of circulating tumor cells in patients with small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 7:512\u2013519. https:\/\/doi.org\/10.1097\/JTO.0b013e31823f125d","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"555_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85\u201391. https:\/\/doi.org\/10.1056\/NEJMoa003034","journal-title":"N Engl J Med"},{"key":"555_CR32","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","volume":"46","author":"V Orian-Rousseau","year":"2010","unstructured":"Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271\u20131277. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.024","journal-title":"Eur J Cancer"},{"key":"555_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3779\/j.issn.1009-3419.2006.05.11","volume":"9","author":"D Pan","year":"2006","unstructured":"Pan D, Hou M, Li H, Yu P, Liu J (2006) Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Zhongguo Fei Ai Za Zhi 9:443\u2013446. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2006.05.11","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"555_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33\u201345. https:\/\/doi.org\/10.1038\/nrm1004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"555_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1471-4914(01)01963-3","volume":"7","author":"E Pure","year":"2001","unstructured":"Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7:213\u2013221","journal-title":"Trends Mol Med"},{"key":"555_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/annonc\/mdh061","volume":"15","author":"S Ramalingam","year":"2004","unstructured":"Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR (2004) Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO 15:247\u2013251","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"555_CR37","first-page":"3719","volume":"58","author":"JA Reeder","year":"1998","unstructured":"Reeder JA, Gotley DC, Walsh MD, Fawcett J, Antalis TM (1998) Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 58:3719\u20133726","journal-title":"Cancer Res"},{"key":"555_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000085621","volume":"51","author":"MA Rosenthal","year":"2005","unstructured":"Rosenthal MA, Gibbs P, Brown TJ et al (2005) Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Chemotherapy 51:132\u2013141. https:\/\/doi.org\/10.1159\/000085621","journal-title":"Chemotherapy"},{"key":"555_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","volume":"10","author":"BJ Roth","year":"1992","unstructured":"Roth BJ, Johnson DH, Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10:282\u2013291","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"555_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/CBM-140424","volume":"14","author":"R Roudi","year":"2014","unstructured":"Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, Shariftabrizi A (2014) Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer biomarkers : section A of Disease markers 14:457\u2013467. https:\/\/doi.org\/10.3233\/CBM-140424","journal-title":"Cancer biomarkers : section A of Disease markers"},{"key":"555_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/sonc.2003.50012","volume":"30","author":"AB Sandler","year":"2003","unstructured":"Sandler AB (2003) Chemotherapy for small cell lung cancer. Semin Oncol 30:9\u201325. https:\/\/doi.org\/10.1053\/sonc.2003.50012","journal-title":"Semin Oncol"},{"key":"555_CR42","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/annonc\/mdq652","volume":"22","author":"A Schmittel","year":"2011","unstructured":"Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22:1798\u20131804. https:\/\/doi.org\/10.1093\/annonc\/mdq652","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"555_CR43","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/S0169-5002(01)00309-9","volume":"33","author":"W Schuette","year":"2001","unstructured":"Schuette W (2001) Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 33(Suppl 1):S99\u2013107","journal-title":"Lung Cancer"},{"key":"555_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1084\/jem.177.2.443","volume":"177","author":"S Seiter","year":"1993","unstructured":"Seiter S, Arch R, Reber S et al (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443\u2013455","journal-title":"J Exp Med"},{"key":"555_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/1759-7714.12303","volume":"6","author":"Y Shi","year":"2015","unstructured":"Shi Y, Hu Y, Hu X, Li X, Lin L, Han X (2015) Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial. Thorac Cancer 6:785\u2013791. https:\/\/doi.org\/10.1111\/1759-7714.12303","journal-title":"Thorac Cancer"},{"key":"555_CR46","first-page":"259S","volume":"123","author":"GR Simon","year":"2003","unstructured":"Simon GR, Wagner H, American College of Chest P (2003) Small Cell Lung Cancer Chest 123:259S\u2013271S","journal-title":"Small Cell Lung Cancer Chest"},{"key":"555_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0046-8177(97)90154-4","volume":"28","author":"TA Tran","year":"1997","unstructured":"Tran TA, Kallakury BV, Sheehan CE, Ross JS (1997) Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28:809\u2013814","journal-title":"Hum Pathol"},{"key":"555_CR48","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","volume":"378","author":"JP van Meerbeeck","year":"2011","unstructured":"van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(11)60165-7","journal-title":"Lancet"},{"key":"555_CR49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755\u2013768. https:\/\/doi.org\/10.1038\/nrc2499","journal-title":"Nat Rev Cancer"},{"key":"555_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0169-5002(96)00625-3","volume":"16","author":"A Wimmel","year":"1997","unstructured":"Wimmel A, Schilli M, Kaiser U et al (1997) Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 16:151\u2013172","journal-title":"Lung Cancer"},{"key":"555_CR51","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/annonc\/mdq036","volume":"21","author":"P Zatloukal","year":"2010","unstructured":"Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810\u20131816. https:\/\/doi.org\/10.1093\/annonc\/mdq036","journal-title":"Ann Oncol"},{"key":"555_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072849","volume":"8","author":"J Zeilstra","year":"2013","unstructured":"Zeilstra J, Joosten SP, Vermeulen L et al (2013) CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One 8:e72849. https:\/\/doi.org\/10.1371\/journal.pone.0072849","journal-title":"PLoS One"},{"key":"555_CR53","first-page":"1993","volume":"16","author":"MQ Zhang","year":"2015","unstructured":"Zhang MQ, Lin X, Li Y, Lu S (2015) Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis Asian Pacific journal of cancer prevention : APJCP 16:1993\u20131995","journal-title":"Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis Asian Pacific journal of cancer prevention : APJCP"},{"key":"555_CR54","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.7314\/APJCP.2014.15.16.6761","volume":"15","author":"S Zhao","year":"2014","unstructured":"Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ, Li WM (2014) Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP 15:6761\u20136766","journal-title":"Asian Pacific journal of cancer prevention : APJCP"},{"key":"555_CR55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc3023","volume":"11","author":"M Zoller","year":"2011","unstructured":"Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254\u2013267. https:\/\/doi.org\/10.1038\/nrc3023","journal-title":"Nat Rev Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0555-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:19:46Z","timestamp":1678540786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,26]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0555-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,26]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}